Published in Medical Letter on the CDC and FDA, April 22nd, 2007
The EquineVet(TM) line contains a core component in Carrington's injectable biologic product, Acemannan Immunostimulant(TM) (AI), marketed under authorization from the United States Department of Agriculture (USDA), for the treatment of fibrosarcoma (a form of soft tissue cancer) in cats and dogs. AI has a polymeric backbone of acetylated mannan called...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.